Literature DB >> 18508079

Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2.

David S Peabody1, Brett Manifold-Wheeler, Alexander Medford, Sheldon K Jordan, Jerri do Carmo Caldeira, Bryce Chackerian.   

Abstract

The high level of immunogenicity of peptides displayed in dense repetitive arrays on virus-like particles makes recombinant VLPs promising vaccine carriers. Here, we describe a platform for vaccine development based on the VLPs of RNA bacteriophage MS2. It serves for the engineered display of specific peptide sequences, but will also allow the construction of random peptide libraries from which specific binding activities can be recovered by affinity selection. Peptides representing the V3 loop of HIV gp120 and the ECL2 loop of the HIV coreceptor, CCR5, were inserted into a surface loop of MS2 coat protein. Both insertions disrupted coat VLP assembly, apparently by interfering with protein folding, but these defects were suppressed efficiently by genetically fusing coat protein's two identical polypeptides into a single-chain dimer. The resulting VLPs displayed the V3 and ECL2 peptides on their surfaces where they showed the potent immunogenicity that is the hallmark of VLP-displayed antigens. Experiments with random-sequence peptide libraries show the single-chain dimer to be highly tolerant of six, eight and ten amino acid insertions. MS2 VLPs support the display of a wide diversity of peptides in a highly immunogenic format, and they encapsidate the mRNAs that direct their synthesis, thus establishing the genotype/phenotype linkage necessary for recovery of affinity-selected sequences. The single-chain MS2 VLP therefore unites in a single structural platform the selective power of phage display with the high immunogenicity of VLPs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18508079      PMCID: PMC2481506          DOI: 10.1016/j.jmb.2008.04.049

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  40 in total

1.  Escherichia coli-based cell-free synthesis of virus-like particles.

Authors:  Bradley C Bundy; Marc J Franciszkowicz; James R Swartz
Journal:  Biotechnol Bioeng       Date:  2008-05-01       Impact factor: 4.530

2.  Multiple presentation of foreign peptides on the surface of an RNA-free spherical bacteriophage capsid.

Authors:  R A Mastico; S J Talbot; P G Stockley
Journal:  J Gen Virol       Date:  1993-04       Impact factor: 3.891

3.  Complementation of RNA binding site mutations in MS2 coat protein heterodimers.

Authors:  D S Peabody; F Lim
Journal:  Nucleic Acids Res       Date:  1996-06-15       Impact factor: 16.971

4.  The influence of antigen organization on B cell responsiveness.

Authors:  M F Bachmann; U H Rohrer; T M Kündig; K Bürki; H Hengartner; R M Zinkernagel
Journal:  Science       Date:  1993-11-26       Impact factor: 47.728

5.  Trinucleotide phosphoramidites: ideal reagents for the synthesis of mixed oligonucleotides for random mutagenesis.

Authors:  B Virnekäs; L Ge; A Plückthun; K C Schneider; G Wellnhofer; S E Moroney
Journal:  Nucleic Acids Res       Date:  1994-12-25       Impact factor: 16.971

6.  Genetic fusion of subunits of a dimeric protein substantially enhances its stability and rate of folding.

Authors:  H Liang; W S Sandberg; T C Terwilliger
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

7.  Encapsidation of heterologous RNAs by bacteriophage MS2 coat protein.

Authors:  G G Pickett; D S Peabody
Journal:  Nucleic Acids Res       Date:  1993-09-25       Impact factor: 16.971

8.  A human recombinant haemoglobin designed for use as a blood substitute.

Authors:  D Looker; D Abbott-Brown; P Cozart; S Durfee; S Hoffman; A J Mathews; J Miller-Roehrich; S Shoemaker; S Trimble; G Fermi
Journal:  Nature       Date:  1992-03-19       Impact factor: 49.962

9.  The synthesis of blocked triplet-phosphoramidites and their use in mutagenesis.

Authors:  A Ono; A Matsuda; J Zhao; D V Santi
Journal:  Nucleic Acids Res       Date:  1995-11-25       Impact factor: 16.971

10.  The refined structure of bacteriophage MS2 at 2.8 A resolution.

Authors:  R Golmohammadi; K Valegård; K Fridborg; L Liljas
Journal:  J Mol Biol       Date:  1993-12-05       Impact factor: 5.469

View more
  54 in total

1.  Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7.

Authors:  Jerri do Carmo Caldeira; Alexander Medford; Rhonda C Kines; Christopher A Lino; John T Schiller; Bryce Chackerian; David S Peabody
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

2.  Cell targeting with hybrid Qβ virus-like particles displaying epidermal growth factor.

Authors:  Jonathan K Pokorski; Marisa L Hovlid; M G Finn
Journal:  Chembiochem       Date:  2011-09-29       Impact factor: 3.164

3.  Structure and stability of icosahedral particles of a covalent coat protein dimer of bacteriophage MS2.

Authors:  Pavel Plevka; Kaspars Tars; Lars Liljas
Journal:  Protein Sci       Date:  2009-08       Impact factor: 6.725

4.  Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine.

Authors:  Zoe Hunter; Hugh D Smyth; Paul Durfee; Bryce Chackerian
Journal:  Vaccine       Date:  2009-10-20       Impact factor: 3.641

5.  Induction of HIV-blocking anti-CCR5 IgA in Peyers's patches without histopathological alterations.

Authors:  Claudia Pastori; Lorenzo Diomede; Assunta Venuti; Gregory Fisher; Jonathan Jarvik; Morgane Bomsel; Francesca Sanvito; Lucia Lopalco
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

Review 6.  Malaria invasion ligand RH5 and its prime candidacy in blood-stage malaria vaccine design.

Authors:  Rosalynn L Ord; Marilis Rodriguez; Cheryl A Lobo
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 7.  Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform.

Authors:  John P O'Rourke; David S Peabody; Bryce Chackerian
Journal:  Curr Opin Virol       Date:  2015-03-29       Impact factor: 7.090

8.  Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles.

Authors:  Carlee E Ashley; Eric C Carnes; Genevieve K Phillips; Paul N Durfee; Mekensey D Buley; Christopher A Lino; David P Padilla; Brandy Phillips; Mark B Carter; Cheryl L Willman; C Jeffrey Brinker; Jerri do Carmo Caldeira; Bryce Chackerian; Walker Wharton; David S Peabody
Journal:  ACS Nano       Date:  2011-06-07       Impact factor: 15.881

9.  Engineering a Virus-like Particle to Display Peptide Insertions Using an Apparent Fitness Landscape.

Authors:  Stephanie A Robinson; Emily C Hartman; Bon C Ikwuagwu; Matthew B Francis; Danielle Tullman-Ercek
Journal:  Biomacromolecules       Date:  2020-09-03       Impact factor: 6.988

10.  Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.

Authors:  Mitchell Tyler; Ebenezer Tumban; Agnieszka Dziduszko; Michelle A Ozbun; David S Peabody; Bryce Chackerian
Journal:  Vaccine       Date:  2014-06-21       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.